Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > REGULATORY
REGULATORY
- Patients Won’t Benefit without Change in Mindset among Researchers: AMED President
April 25, 2018
- ICER-Based Price Tweaks “Scientifically Difficult,” Impact on Cost Cuts Limited: Prof.
April 25, 2018
- Tap Data from “Specified Clinical Research” for Early Trial, Conditional Approval: JPMA Official
April 24, 2018
- Label Revision Ordered for Keytruda with Sclerosing Cholangitis as ADR
April 20, 2018
- MHLW Sees Solid Inquiry Numbers for Conditional Early Approval System: Official
April 19, 2018
- Generic Industry Asks for Govt Support for Continuous Manufacturing to Boost Int’l Competitiveness: Public-Private Confab
April 17, 2018
- No Company Supports New Price Maintenance Premium Scheme: FPMAJ Survey
April 17, 2018
- Pharma Leaders Air Grievances on Pricing Reform Package at New MHLW Confab
April 17, 2018
- Generic Drug Makers Required to Improve Package Inserts by Adding Information from Clinical Studies: MHLW Notification
April 17, 2018
- Xeljanz’s Ulcerative Colitis Use Up for MHLW Panel Review on April 27
April 16, 2018
- MHLW to Draft GL on Detailing Activities by Drug Reps as Early as Summer
April 13, 2018
- MHLW Compiles Drug Reuse Guide to Reduce Leftover Drug Solutions
April 13, 2018
- AZ’s PD-L1 Inhibitor Durvalumab Up for MHLW Panel Review on April 25
April 13, 2018
- MHLW to Issue Optimal Use Guidelines for Dupixent, Tecentriq
April 12, 2018
- MHLW Panel Starts Discussions on PMD Law Amendment; Will First Verify Results of Previous Amendment
April 12, 2018
- Chuikyo Holds 1st Listing Discussions since Overhaul, US Reference Prices Show Marked Declines after Rule Change
April 12, 2018
- Chuikyo Payer Rep Questions New Premium System for Cost-Based Pricing Method
April 12, 2018
- MOF Calls for Using CEA to Make Reimbursement Decisions for Pricy Drugs
April 12, 2018
- Pricing OK’ed for Dupixent, Tecentriq, Lynparza, and More; Parmodia Skips Listing Yet Again
April 11, 2018
- Doctor Calls for Incentives for Effective, Lower-Cost Existing Drugs: LDP Taskforce
April 10, 2018
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…